ADJUVANT THERAPY OF PATIENTS WITH REGIONAL LYMPH NODE METASTASES OF SKIN MELANOMA
The paper reports results of combined application of alpha 2-b interferon and dacarbazine (Group 1) as compared to monointerferon therapy (Group 2) in adjuvant regime in patients with regional lymph node metastases of skin melanoma. The 3-year survival rate is shown to be 54.3 ± 7.9 and 65.5 ± 5.8% in Groups 1 and 2 respectively. The 3-year relapse-free survival rate was 31.9 ± 7.4 and 40.9 ± 6.0% respectively. In other words, combination of alpha-2b interferon with dacarbazine in an adjuvant regime does not improve the remote results as compared to alpha-2b interferon monotherapy in patients with regional lymph node metastases of skin melanoma.
No comments » Add comment